应用灯盏花素片治疗后，14例P 3潜伏期显著缩短，HDS评分上升。
After breviscapine treatment, P3 latency decreased in 14 patients and HDS increased in all the patients.
结论优化处方的灯盏花素分散片其体外溶出度明显优于普通片。
CONCLUSION The in-vitro dissolubility of the optimized dispersed tablet is better than that of commontable.
目的以羟丙甲基纤维素为骨架材料制得灯盏花素缓释片，并对释药机制进行探讨。
OBJECTIVE Breviscapine sustained-release tablets(BST)were formulated with hydroxypropyl-methylcellulose as the matrix material and the release mechanism of the tablets was studied.
结果：按优选处方制得的灯盏花素口腔崩解片，能在35s内崩解完全，口感良好，溶出度明显高于普通片。
RESULTS: The tablets prepared were finer in appearance, disintegrated within 35 s, with desirable taste. The dissolution rate was faster than breviscapine ordinary tablets.
方法：采用均匀设计试验法，以片剂崩解时限为指标，筛选灯盏花素口腔崩解片的最佳处方。
METHODS: to adopt the multifactor and multilevel uniform design to optimize the preparation prescription, disintegrating time as the assessment index.
目的考察处方中组分对灯盏花素分散片制剂的影响。
OBJECTIVE To examine the effects of the ingredients on Breviscarpin dispersed tablet.
方法以崩解时限为指标，采用正交设计试验，对灯盏花素分散片处方进行筛选。
METHODS The formulae of Breviscarpin dispersed tablet were optimized in terms of disintegrating time by orthogonal design test.
方法以崩解时限为指标，采用正交设计试验，对灯盏花素分散片处方进行筛选。
METHODS The formulae of Breviscarpin dispersed tablet were optimized in terms of disintegrating time by orthogonal design test.
应用推荐